Frontier Pharma: Rheumatoid Arthritis -
Cytokine Mediators and Kinase Inhibitors
Dominate First-in-Class Product Innovation
“The large target patient population and the
relatively high annual cost of therapy have resulted
in a crowded, highly lucrative market.”
Summary
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease
that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs
when a number of aberrant cell signaling events trigger chronic inflammation of the synovium - the
soft tissue of the joint - leading to pain, joint stiffness, and eventually deformity and disability.
With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA
are substantial. The large target patient population and the relatively high annual cost of therapy
have resulted in a crowded, highly lucrative market.
Treatment options have improved and diversified substantially over the past two decades, largely
owing to the advent of biologics. Despite this, considerable unmet needs remain within RA.
Consequently, opportunities for future drug developments remain significant, particularly for first-
in-class innovation, which is the area most likely to produce substantial clinical advances.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontier-
pharma-rheumatoid-arthritis
Follow Us: